Article info
PDFUterine Cancer
Phase 2 Trial of Nonpegylated Doxorubicin (Myocet) as Second-Line Treatment in Advanced or Recurrent Endometrial Cancer
- Address correspondence and reprint requests to Domenica Lorusso, MD, Department of Gynecologic Oncology, Catholic University of the Sacred Heart, Largo Agostino Gemelli 8, IT-00168 Rome, Italy. E-mail: kettalorusso{at}libero.it.
Citation
Phase 2 Trial of Nonpegylated Doxorubicin (Myocet) as Second-Line Treatment in Advanced or Recurrent Endometrial Cancer
Publication history
- Received March 31, 2011
- First published November 1, 2011.
Online issue publication
February 26, 2019
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright © 2011 by IGCS and ESGO